Dan Jones

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Elias Jabbour, Hagop M. Kantarjian, Dan Jones et al. · Leukemia · 2006 · 385 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +9

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

Elihu H. Estey, Guillermo Garcia‐Manero, Alessandra Ferrajoli et al. · Blood · 2005 · 378 citations · Full text

Effective Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

Farhad Ravandi, E Estey, Dan Jones et al. · Journal of Clinical Oncology · 2008 · 373 citations · Full text

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Francis J. Giles, Jörge E. Cortes, Dan Jones et al. · Blood · 2006 · 361 citations · Full text

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

Farhad Ravandi, Susan O’Brien, Deborah Thomas et al. · Blood · 2010 · 343 citations · Full text